Clovis Oncology was an American pharmaceutical company founded in 2009 by Patrick Mahaffy in Boulder, Colorado, specializing in oncology treatments. Its most notable product, rucaparib (Rubraca), a PARP inhibitor for advanced ovarian cancer, received accelerated FDA approval in December 2016. However, another drug, rociletinib, led to a $20 million SEC settlement in September 2018 due to claims of exaggerated efficacy in patient trials.

Despite a product pipeline and being publicly traded, the company struggled financially, never achieving profitability since its inception. This ultimately led to Clovis Oncology filing for Chapter 11 bankruptcy in December 2022, with rucaparib being sold off the following year as part of the proceedings.